Key Highlights

  • The board declared an $0.88 quarterly Dividend on August 5, payable October 30 to holders of record on September 30.
  • The company states the dividend is unchanged from the previous quarter and up 4.8% versus the prior year.
  • Second-quarter net sales rose 9.4% to $6.589 billion, with organic net sales growth of 9.0%.
  • GAAP diluted EPS was $3.30, up 44.1%, and adjusted diluted EPS, a non-GAAP measure, was $3.69, up 17.9%.

Overview

Stryker Corporation (NYSE:SYK) declared a quarterly dividend of $0.88 per share on August 5, 2026, payable October 30 to shareholders of record on September 30. The dividend yields 1.29%. Second-quarter GAAP diluted EPS was $3.30 and adjusted diluted EPS, a non-GAAP measure, was $3.69. Reported net sales rose 9.4% and organic net sales rose 9.0%.

Dividend Program and Shareholder Returns

The board declared a quarterly dividend of $0.88 per share on August 5, 2026. It is payable October 30 to shareholders of record on September 30, and the stock trades ex-dividend on September 30.

The announcement states that the dividend is an increase of 4.8% versus the prior year and unchanged from the previous quarter. The declaration came after the company reported second-quarter results, which included growth in both operating groups.

About the Company

Stryker reports two operating groups, MedSurg and Neurotechnology, and Orthopaedics, which together made up its second-quarter net sales. Its second-quarter release reports GAAP results alongside adjusted results, which it identifies as non-GAAP measures. Kevin A. Lobo is Chair and Chief Executive Officer.

Second-Quarter Sales and Earnings

Reported net sales were $6.589 billion, up 9.4%. Organic net sales growth was 9.0%, and constant currency growth was 9.0%.

GAAP net Earnings were $1.276 billion, up 44.3%, and GAAP diluted EPS was $3.30, up 44.1%. Adjusted net earnings, a non-GAAP measure, were $1.424 billion, up 17.6%, and adjusted diluted EPS was $3.69, up 17.9%.

GAAP net earnings of $1.276 billion compare with adjusted net earnings of $1.424 billion, and the company reports both measures in its release. The reported Operating Margin was 25.2%, and the adjusted operating margin, a non-GAAP measure, was 27.4%, up 170 basis points.

Segment Growth and Full-Year Guidance

MedSurg and Neurotechnology net sales were $3.6 billion, up 9.7% on a reported basis and 9.2% organically. Orthopaedics net sales were $3.0 billion, up 9.1% reported and 8.6% organically.

Chair and Chief Executive Officer Kevin A. Lobo said the company made significant progress in its recovery from the cyber incident, and that sales, Earnings Per Share and Operating Cash Flow all grew in the second quarter.

For 2026, the company guides to organic net sales growth of 8.3% to 9.3% and adjusted diluted EPS of $14.95 to $15.10. The adjusted EPS guidance is a non-GAAP measure, and the company reports the growth guidance on an organic basis, which is separate from reported net sales growth.

Outlook

The cyber incident recovery, organic growth of 9.2% in MedSurg and Neurotechnology and 8.6% in Orthopaedics, the operating margin of 27.4% on an adjusted basis, the gap between GAAP and adjusted EPS, the full-year guidance ranges and the board's quarterly declarations are the relevant considerations. The second quarter is the most recent reported period.